An update on the ‘danger theory’ in inhibitor development in hemophilia A

References

• Carcao M. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost [Internet]. 2012;38:727–734. Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1326786
   PubMed Web of Science ®Google Scholar
• Tabriznia-Tabrizi S, Gholampour M, Mansouritorghabeh H. A close insight to factor VIII inhibitor in the congenital hemophilia A. Expert Rev Hematol [Internet]. 2016;9:903–913.
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418–435.
   PubMed Web of Science ®Google Scholar
• Gouw S, van Den Berg H, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood [Internet]. 2013;121:4046–4055. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23553768
   PubMed Web of Science ®Google Scholar
• Walsh CE, Jimenez-Yuste V, Auerswald G, et al. The burden of inhibitors in haemophilia patients. Thromb Haemost. 2016;116:S10–7.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors : the COCIS study group. Blood. 2003;102:2358–2363.
   PubMed Web of Science ®Google Scholar
• Hay CRM, Dimichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335–1344.
   PubMed Web of Science ®Google Scholar
• Valentino LA, Kempton CL, Kruse-Jarres R, et al. US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia. 2015;21:559–567.
   PubMed Web of Science ®Google Scholar
• Rocino A, Cortesi PA, Scalone L, et al. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia. 2016;22:96–102.
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.
   PubMed Web of Science ®Google Scholar
• White GC, Kempton CL, Grimsley A, et al. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost. 2005;3:1676–1681.
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Navarrete AM, André S, et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood. 2008;112:240–249.
   PubMed Web of Science ®Google Scholar
• Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost. 2009;7:1446–1456.
   PubMed Web of Science ®Google Scholar
• Wroblewska A, Reipert BM, Pratt KP, et al. Dangerous liaisons : how the immune system deals with factor VIII. J Thromb Haemost. 2013;11:47–55.
   PubMed Web of Science ®Google Scholar
• Georgescu MT, Lai JD, Hough C, et al. War and peace: factor VIII and the adaptive immune response. Cell Immunol. 2016;301:2–7.
   PubMed Web of Science ®Google Scholar
• Herczenik E, van Haren SD, Wroblewska A, et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain. J Allergy Clin Immunol [Internet]. 2012;129:501–509.e5.
   PubMed Web of Science ®Google Scholar
• Wroblewska A, van Haren SD, Herczenik E, et al. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood. 2012;119:5294–5300.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Navarrete A-M, Bayry J, et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2007;104:1–6.
   Web of Science ®Google Scholar
• André S, Meslier Y, Dimitrov JD, et al. A cellular viewpoint of anti-FVIII immune response in hemophilia a. Clin Rev Allergy Immunol. 2009;37:105–113.
   PubMed Web of Science ®Google Scholar
• Navarrete A, Dasgupta S, Delignat S, et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. J Thromb Haemost. 2009;7:1816–1823.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Ettingshausen CE, Goudemand J, et al. New findings on inhibitor development: from registries to clinical studies. Haemophilia [Internet]. 2017;23:4–13.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, van Den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648–4654.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I. Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Res Pract Thromb Haemost. 2018;2:220–227.
   PubMed Web of Science ®Google Scholar
• Calvez T, Chambost H, D’Oiron R, et al. Analyses of the FranceCoag cohort support differences in immunogenicity among one VIII brands in boys with severe hemophilia A. Haematologica. 2018;103:179–189.
   PubMed Web of Science ®Google Scholar
• Garagiola I, Palla R, Peyvandi F. Risk factors for inhibitor development in severe hemophilia A. Thromb Res [Internet]. 2018;168:20–27.
   PubMed Web of Science ®Google Scholar
• Repessé Y, Peyron I, Dimitrov JD, et al. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica. 2013;98:1650–1655.
   PubMed Web of Science ®Google Scholar
• Schwaab R, Brackmann H, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402–1406.
   PubMed Web of Science ®Google Scholar
• Gouw S, van der Bom J, van Den Berg H, et al. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia. 2011;17:275–281.
   PubMed Web of Science ®Google Scholar
• Goodeve A, Peake I. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost. 2003;29:23–30.
   PubMed Web of Science ®Google Scholar
• Lillicrap D. The role of immunomodulation in the management of factor VIII inhibitors. Hematol Am Soc Hematol Educ Progr [Internet]. 2006:421–425. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17124093
   PubMedGoogle Scholar
• Anderton SM, Wraith DC. Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol [Internet]. 2002;2:487–498. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12094223
   PubMed Web of Science ®Google Scholar
• Walker LSK, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol [Internet]. 2002;2:11–19. Available from: http://www.nature.com/doifinder/10.1038/nri701
   PubMed Web of Science ®Google Scholar
• Bluestone J, Abbas A. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253–257.
   PubMed Web of Science ®Google Scholar
• Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: A systematic review. J Thromb Haemost. 2010;8:1256–1265.
   PubMed Web of Science ®Google Scholar
• Franchini M, Coppola A, Rocino A, et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost. 2013;39:752–766.
   PubMed Web of Science ®Google Scholar
• Marcucci M, Mancuso MEL, Santagostino E, et al. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost. 2015;113:958–967.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med [Internet]. 2016;374:2054–2064. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27223147%5Cnhttp://www.nejm.org/doi/10.1056/NEJMoa1516437
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Shi Q, Bonanad S, et al. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development. Haemophilia. 2014;20:2–16.
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A: A critical literature review. Thromb Haemost. 2010;104:931–940.
   PubMed Web of Science ®Google Scholar
• Di Minno G, Coppola A. A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors? Blood Transfus [Internet]. 2011;9 Suppl 2:s14–s20. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3159912&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Hironakaso T, Furukawas K, Fournelll MA, et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem. 1992;267:8012–8020.
   PubMed Web of Science ®Google Scholar
• Kannicht C, Ramström M, Kohla G, et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res [Internet]. 2013;131:78–88.
   PubMed Web of Science ®Google Scholar
• van Helden PMW, van Haren SD, Fijnvandraat K, et al. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors. Haemophilia. 2010;16:35–43.
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model : a renewed sense of self. Science. 2002;296:301–306.
   PubMed Web of Science ®Google Scholar
• Fekety FR. The Clonal Selection Theory of Acquired Immunity. Yale J Biol Med. 1960 Jun;32(6):480.
   Google Scholar
• Burnet F. A modification of Jerne’s theory of antibody production using the concept of clonal selection. CA Cancer J Clin. 1976;26:119–121.
   PubMedGoogle Scholar
• Bretscher P, Cohn M. A theory of self-nonself discrimination. Science. 1970;69:1042–1049.
   Google Scholar
• Janeway C. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today. 1992;13:11–16.
   PubMedGoogle Scholar
• Medzhitov R, Janeway C. How does the immune system distinguish self from nonself? Semin Immunol. 2000;12:185–188.
   PubMed Web of Science ®Google Scholar
• Matzinger P. Essay 1 : the danger model in its historical context. Scand J Immunol. 2001;54:4–9.
   PubMed Web of Science ®Google Scholar
• Kono H, Rock K. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8:279–289.
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans J, Rock K. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516–521.
   PubMed Web of Science ®Google Scholar
• Lotze M, Tracey K. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–342.
   PubMed Web of Science ®Google Scholar
• Bianchi M. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1–5.
   PubMed Web of Science ®Google Scholar
• Hwang PF, Porterfield N, Pannell D, et al. Trauma is danger. J Transl Med. 2011;9:1–10.
   Web of Science ®Google Scholar
• Seong S, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469–478.
   PubMed Web of Science ®Google Scholar
• Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16:747–766.
   PubMed Web of Science ®Google Scholar
• Lövgren KM, Sondergaard H, Skov S, et al. Non-genetic risk factors in haemophilia A inhibitor management – the danger theory and the use of animal models. Haemophilia. 2016;22:657–666.
   PubMed Web of Science ®Google Scholar
• Lövgren K, Søndergaard H, Skov S, et al. Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A. J Thromb Haemost. 2016;14:747–756.
   PubMed Web of Science ®Google Scholar
• Reipert B, Arruda V, Lillicrap D. Animal models of inhibitors. Haemophilia. 2010;16:47–53.
   PubMed Web of Science ®Google Scholar
• Lillicrap D, Fijnvandraat K, Santagostino E. Inhibitors - genetic and environmental factors. Haemophilia. 2014;20:87–93.
   PubMed Web of Science ®Google Scholar
• Miller L, Weissmüller S, Ringler E, et al. Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products. Thromb Haemost. 2015;114:268–276.
   PubMed Web of Science ®Google Scholar
• Miller L, Ringler E, Kistner K, et al. Human dendritic cells synergistically activated by FVIII plus LPS induce activation of autologous CD4+ T cells. Thromb Haemost. 2018;118:688–699.
   PubMed Web of Science ®Google Scholar
• Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417–430.
   PubMed Web of Science ®Google Scholar
• Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114:2367–2374.
   PubMed Web of Science ®Google Scholar
• Pfistershammer K, Stöckl J, Siekmann J, et al. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost. 2006;96:309–316.
   PubMed Web of Science ®Google Scholar
• Skupsky J, Zhang AH, Su Y, et al. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood. 2009;114:4741–4748.
   PubMed Web of Science ®Google Scholar
• Meeks SL, Cox CL, Healey JF, et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood. 2012;120:2512–2520.
   PubMed Web of Science ®Google Scholar
• Gangadharan B, Delignat S, Ollivier V, et al. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A. J Thromb Haemost. 2014;12:2065–2069.
   PubMed Web of Science ®Google Scholar
• Moorehead P, Waters B, Sponagle K, et al. Surgical injury alone does not provoke the development of factor VIII inhibitors in mouse models of hemophilia A. Blood. 2012;120:627.
   Google Scholar
• Peyron I, Dimitrov J, Delignat S, et al. Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice. Haemophilia. 2015;21:e94–8.
   PubMed Web of Science ®Google Scholar
• Lövgren K, Christensen K, Majewski W, et al. Acute haemarthrosis in the haemophilia A rat generates a local and systemic proinflammatory response. Thromb Haemost. 2017;117:2092–2104.
   PubMed Web of Science ®Google Scholar
• Lai J, Moorehead P, Sponagle K, et al. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A. Blood. 2016;127:3439–3449.
   PubMed Web of Science ®Google Scholar
• White B, Cotter M, Byrne M, et al. High responding factor VIII inhibitors in mild haemophilia - Is there a link with recent changes in clinical practice? Haemophilia. 2000;6:113–115.
   PubMed Web of Science ®Google Scholar
• Sharathkumar A, Lillicrap D, Blanchette V, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost. 2003;1:1228–1236.
   PubMed Web of Science ®Google Scholar
• Eckhardt C, Menke L, van Ommen C, et al. Intensive peri-operative use of factor VIII and the Arg593 → Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost. 2009;7:930–937.
   PubMed Web of Science ®Google Scholar
• Gouw S, van Den Berg H, Le Cessie S, et al. Treatment characteristics and the risk of inhibitor development: A multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost. 2007;5:1383–1390.
   PubMed Web of Science ®Google Scholar
• Hashemi S, Fischer K, Moons K, et al. Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A. Haemophilia. 2015;21:227–233.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Mancuso M, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol. 2005;130:422–427.
   PubMed Web of Science ®Google Scholar
• Maclean P, Richards M, Williams M, et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia. 2011;17:282–287.
   PubMed Web of Science ®Google Scholar
• Vézina C, Carcao M, Infante-Rivard C, et al. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010. Haemophilia. 2014;20:771–776.
   PubMed Web of Science ®Google Scholar
• McMillan C, Shapiro S, Whitehurst D, et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood. 1988;71:344–348.
   PubMed Web of Science ®Google Scholar
• Platokouki H, Fischer K, Gouw S, et al. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia. 2018;24:283–290.
   PubMed Web of Science ®Google Scholar
• Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16:256–262.
   PubMed Web of Science ®Google Scholar
• Auerswald G, Kurnik K, Aledort LM, et al. The EPIC study: A lesson to learn. Haemophilia. 2015;21:622–628.
   PubMed Web of Science ®Google Scholar
• Varthaman A, Lacroix-Desmazes S. Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance? Haematologica. 2019;104:236–244.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu J, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med [Internet]. 2017;377:809–818.
   PubMed Web of Science ®Google Scholar
• Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: A randomized first human dose trial. J Thromb Haemost. 2015;13:743–754.
   PubMed Web of Science ®Google Scholar
• Pasi K, Rangarajan A, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med [Internet]. 2017;377:819–828.
   PubMed Web of Science ®Google Scholar
• Qian J, Collins M, Sharpe AH, et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood [Internet]. 2000;95:1324–1329. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10666206%5Cnhttp://bloodjournal.org/content/bloodjournal/95/4/1324.full.pdf%5Cnhttp://www.bloodjournal.org/content/bloodjournal/95/4/1324.full.pdf
   PubMed Web of Science ®Google Scholar
• Reipert BM, Sasgary M, Ahmad RU, et al. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost. 2001;86:1345–1352.
   PubMed Web of Science ®Google Scholar
• Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood. 2001;97:2750–2757.
   PubMed Web of Science ®Google Scholar
• Hausl C, Ahmad RU, Schwarz HP, et al. Preventing restimulation of memory B cells in hemophilia A: A potential new strategy for the treatment of antibody-dependent immune disorders. Blood. 2004;104:115–122.
   PubMed Web of Science ®Google Scholar
• Astermark J, Berntorp E, White GC, et al. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia. 2001;7:267–272.
   PubMed Web of Science ®Google Scholar
• Hay C, Ollier W, Pepper L, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO inhibitor working party. Thromb Haemost. 1997;77:234–237.
   PubMed Web of Science ®Google Scholar
• Astermark J, Oldenburg J, Pavlova A, et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006;107:3167–3172.
   PubMed Web of Science ®Google Scholar
• Astermark J, Wang X, Oldenburg J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. J Thromb Haemost [Internet]. 2007;5:263–265. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17269936
   PubMed Web of Science ®Google Scholar
• Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009;7:2006–2015.
   PubMed Web of Science ®Google Scholar
• Chalmers E, Brown S, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007;13:149–155.
   PubMed Web of Science ®Google Scholar
• Eckhardt C, Van der Bom J, van der Naald M, et al. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost. 2011;9:1948–1958.
   PubMed Web of Science ®Google Scholar